A study found some mutations that are already targeted by approved or investigational drugs for prostate cancer, along with dozens of targets that should be considered as candidates for future trials.

In this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.

AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial.

In KEYNOTE-189, a pembrolizumab/chemo combination yielded OS and PFS benefits in patients with advanced NSCLC.

In this video, Dr. Edison Liu describes a novel patient-derived xenograft platform that might enable development of a mouse-based clinical trials program.

A simple prognostic tool could be used to identify patients with HR-positive breast cancer who underwent 5 years of endocrine treatment and who might be at higher risk of late distant recurrence.

In this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in ovarian cancer, and the importance of understanding how resistance to these agents develops.

Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis.